MIM
ECYT

Monashee Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Monashee Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Hold
0
– – – 37
2018
Q2 		– Sell
-145,121
Closed -$1.32M – 244
2018
Q1 		$1.32M Buy
+145,121
New +$801K 0.36% 69
2017
Q4 		– Hold
0
– – – 124

Other funds holding ECYT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Monashee Investment Management's ECYT Position: Q3 2018 in Review

Monashee Investment Management held its Endocyte, Inc. Common Stock (ECYT) position steady in Q3 2018 at 0 shares worth $3.02M. The position accounts for 0.64% of the portfolio, ranked #37.

Monashee Investment Management first reported a position in ECYT in Q1 2018 and has held it in 1 quarter since. The position peaked at $1.32M in Q1 2018. 139 funds tracked by Wall St. Rank hold ECYT as of Q3 2018.

  • Monashee Investment Management held 0 shares of Endocyte, Inc. Common Stock worth $3.02M as of Q3 2018.
  • Monashee Investment Management left its Endocyte, Inc. Common Stock share count unchanged in Q3 2018.
  • Endocyte, Inc. Common Stock made up 0.64% of Monashee Investment Management's portfolio in Q3 2018, its #37 holding.
  • Monashee Investment Management first reported a position in Endocyte, Inc. Common Stock in Q1 2018 and has held it in 1 quarter since.
  • Monashee Investment Management's Endocyte, Inc. Common Stock position peaked at $1.32M in Q1 2018.
  • 139 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2018.

Based on Monashee Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.